Literature DB >> 3993530

Clinical significance of ventricular fibrillation-flutter induced by ventricular programmed stimulation.

L A DiCarlo, F Morady, A B Schwartz, E N Shen, J M Baerman, R B Krol, M M Scheinman, R J Sung.   

Abstract

Two hundred twenty-four patients underwent ventricular programmed stimulation (VPS) without prior documentation of the clinical occurrence of sustained ventricular tachycardia (VT) or ventricular fibrillation-flutter (VF). Indications for VPS were: palpitations or nonsustained VT during ambulatory monitoring (85 patients), syncope or presyncope (137 patients), and a family history of sudden death (two patients). Sustained VF requiring transthoracic defibrillation was initiated by VPS in 18 patients (8.0%). Four patients were treated for inducible VF with antiarrhythmic agents directed by electropharmacologic testing; five patients were treated empirically; nine patients received no therapy. No patient has had a cardiac arrest or sudden death during a follow-up period 25.2 +/- 13.8 months (mean +/- standard deviation). VF was initiated by two ventricular extrastimuli in three patients and by three extrastimuli in 15 patients. The incidence of VF was similar in patients with and without previous symptoms (8.8% vs 6.9%) or heart disease (7.1% vs 9.6%). It was significantly higher when VPS at three ventricular sites with a current of 5 mA (pulse width 2 msec) was compared to programmed stimulation at two ventricular sites with a current twice diastolic threshold (pulse width 2 msec) (15.2% vs 3.0%, p less than 0.05). VF initiated by VPS in patients without prior VT or VF appears to be a nonspecific finding. Antiarrhythmic therapy for VF may not be necessary in these patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3993530     DOI: 10.1016/0002-8703(85)90235-2

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  8 in total

1.  Prospective clinical evaluation of a programmed atrial stimulation protocol for induction of sustained atrial fibrillation and flutter.

Authors:  R B Krol; S Saksena; A Prakash; I Giorgberidze; P Mathew
Journal:  J Interv Card Electrophysiol       Date:  1999-03       Impact factor: 1.900

2.  Electrophysiological studies of transgenic long QT type 1 and type 2 rabbits reveal genotype-specific differences in ventricular refractoriness and His conduction.

Authors:  Katja E Odening; Malcolm Kirk; Michael Brunner; Ohad Ziv; Peem Lorvidhaya; Gong Xin Liu; Lorraine Schofield; Leonard Chaves; Xuwen Peng; Manfred Zehender; Bum-Rak Choi; Gideon Koren
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-06-25       Impact factor: 4.733

3.  Nicorandil normalizes prolonged repolarisation in the first transgenic rabbit model with Long-QT syndrome 1 both in vitro and in vivo.

Authors:  Jürgen Biermann; Kezhong Wu; Katja E Odening; Stefan Asbach; Gideon Koren; Xuwen Peng; Manfred Zehender; Christoph Bode; Michael Brunner
Journal:  Eur J Pharmacol       Date:  2010-10-17       Impact factor: 4.432

4.  Induction of ventricular arrhythmias by programmed ventricular stimulation: a prospective study on the effects of stimulation current on arrhythmia induction.

Authors:  P L Weissberg; A Broughton; R W Harper; A Young; A Pitt
Journal:  Br Heart J       Date:  1987-11

5.  Clinical significance of rapid ventricular tachycardia (> 270 beats per minute) provoked at programmed stimulation in patients without confirmed rapid ventricular arrhythmias.

Authors:  B Brembilla-Perrot; A Terrier de la Chaise; S Briançon; M Takoordial; C Suty-Selton; B Thiel; J L Brua
Journal:  Br Heart J       Date:  1993-01

6.  Comparative follow up of patients with implanted cardioverter-defibrillators after induction of sustained monomorphic ventricular tachycardias or ventricular fibrillation by programmed stimulation.

Authors:  M Meyborg; R Mura; C Tiefenbacher; R Becker; J Michaelsen; F Niroomand
Journal:  Heart       Date:  2003-06       Impact factor: 5.994

7.  Experiments Investigating the Competitive Growth Advantage of Two Different Genotypes of Human Metapneumovirus: Implications for the Alternation of Genotype Prevalence.

Authors:  Zhen Zhou; Pan Zhang; Yuxia Cui; Yongbo Zhang; Xian Qin; Rongpei Li; Ping Liu; Ying Dou; Lijia Wang; Yao Zhao
Journal:  Sci Rep       Date:  2020-02-18       Impact factor: 4.379

8.  A Reproducible Protocol to Assess Arrhythmia Vulnerability in silico: Pacing at the End of the Effective Refractory Period.

Authors:  Luca Azzolin; Steffen Schuler; Olaf Dössel; Axel Loewe
Journal:  Front Physiol       Date:  2021-04-01       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.